国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2008年
2期
101-102,110
,共3页
肝炎病毒,乙型%核苷类药物%疗效
肝炎病毒,乙型%覈苷類藥物%療效
간염병독,을형%핵감류약물%료효
Hepatitis B virus%Nucleotide analog%Prognosis
目的 研究HBV前S1抗原(Pre-S1)在指导核苷(酸)类药物抗病毒治疗上的意义.方法 将HBeAg阳性患者经拉米夫定治疗获得完全应答并维持疗效6个月以上停药者以Pre-S1是否阳性分成两组,比较两组的远期疗效.结果 Pre-S1阴性组一年、二年远期持续应答率分别为80%、21.05%,差异有统计学意义(P＜0.01).阳性组患者一年、二年远期持续应答率分别为65%、10.53%,差异有统计学意义(P＜0.01).结论 检测Pre-S1可作为判断慢性乙型肝炎患者经核苷(酸)类药物治疗完全应答后远期疗效和预后的重要指标.
目的 研究HBV前S1抗原(Pre-S1)在指導覈苷(痠)類藥物抗病毒治療上的意義.方法 將HBeAg暘性患者經拉米伕定治療穫得完全應答併維持療效6箇月以上停藥者以Pre-S1是否暘性分成兩組,比較兩組的遠期療效.結果 Pre-S1陰性組一年、二年遠期持續應答率分彆為80%、21.05%,差異有統計學意義(P＜0.01).暘性組患者一年、二年遠期持續應答率分彆為65%、10.53%,差異有統計學意義(P＜0.01).結論 檢測Pre-S1可作為判斷慢性乙型肝炎患者經覈苷(痠)類藥物治療完全應答後遠期療效和預後的重要指標.
목적 연구HBV전S1항원(Pre-S1)재지도핵감(산)류약물항병독치료상적의의.방법 장HBeAg양성환자경랍미부정치료획득완전응답병유지료효6개월이상정약자이Pre-S1시부양성분성량조,비교량조적원기료효.결과 Pre-S1음성조일년、이년원기지속응답솔분별위80%、21.05%,차이유통계학의의(P＜0.01).양성조환자일년、이년원기지속응답솔분별위65%、10.53%,차이유통계학의의(P＜0.01).결론 검측Pre-S1가작위판단만성을형간염환자경핵감(산)류약물치료완전응답후원기료효화예후적중요지표.
Objective To evaluate the significance of HBV Pre-S1 antigen detection in clinical evaluation of antiviral therapy by nucleotide analogs .Method HBeAg positive patients which had combined complete response and sustained for 6 months after lamivudine therapy were divided into two groups according Pre-S1 detection and their therapeutic effect was compared.Results The response rates of one year and two year of HBV Pre-S1 antigen positive and negative were 80%and 21.05% respectively,and showed statistical difference(P＜0.01).The response rates of one year and two year of HBV Pre-S1 antigen negative were 65% and 10.53% respectively,and showed statistical difference(P＜0.01).Conclusions The detection of HBV Pre-S1 antigen may become an index that iudges long-term effect of chronic hepatitis patients after nucleotide analogs therapy.
